ATE291898T1 - Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason - Google Patents

Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason

Info

Publication number
ATE291898T1
ATE291898T1 AT00985666T AT00985666T ATE291898T1 AT E291898 T1 ATE291898 T1 AT E291898T1 AT 00985666 T AT00985666 T AT 00985666T AT 00985666 T AT00985666 T AT 00985666T AT E291898 T1 ATE291898 T1 AT E291898T1
Authority
AT
Austria
Prior art keywords
fluticasone
aerosol formulation
pharmaceutical aerosol
formulation containing
salmeterol
Prior art date
Application number
AT00985666T
Other languages
German (de)
English (en)
Inventor
Alan Leslie Cripps
Paul Johnson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930878.5A external-priority patent/GB9930878D0/en
Priority claimed from GB0018686A external-priority patent/GB0018686D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE291898T1 publication Critical patent/ATE291898T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00985666T 1999-12-24 2000-12-21 Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason ATE291898T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930878.5A GB9930878D0 (en) 1999-12-24 1999-12-24 Pharmaceutical formulation
GB0018686A GB0018686D0 (en) 2000-07-28 2000-07-28 Pharmaceutical formulation
PCT/GB2000/004939 WO2001047493A1 (en) 1999-12-24 2000-12-21 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

Publications (1)

Publication Number Publication Date
ATE291898T1 true ATE291898T1 (de) 2005-04-15

Family

ID=26244762

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00985666T ATE291898T1 (de) 1999-12-24 2000-12-21 Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason

Country Status (8)

Country Link
US (1) US20030032632A1 (https=)
EP (1) EP1248597B1 (https=)
JP (1) JP2003518484A (https=)
AT (1) ATE291898T1 (https=)
AU (1) AU2206801A (https=)
DE (1) DE60019167T2 (https=)
ES (1) ES2238334T3 (https=)
WO (1) WO2001047493A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
US20050048001A1 (en) * 1999-11-23 2005-03-03 Cripps Alan Leslie Pharmaceutical formulations of salmeterol
DE60017450T2 (de) * 1999-11-23 2006-03-02 Glaxo Group Ltd., Greenford Pharmazeutische formulierungen enthaltend salmeterol
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
JP5392880B2 (ja) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
GB2367011A (en) * 2000-08-26 2002-03-27 Glaxo Group Ltd Metered dose inhaler for salmeterol
AR030516A1 (es) * 2000-08-31 2003-08-20 Glaxo Group Ltd Uso de una combinacion de salmeterol y fluticasona
GB0021927D0 (en) * 2000-09-07 2000-10-25 Glaxo Group Ltd Use of pharmaceutical combination
GB0105560D0 (en) * 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
DK1542904T3 (da) * 2002-08-27 2008-04-21 Schering Corp Fremgangsmåde til fremstilling af formuleringer til en inhalator med målte doser
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1811981B1 (en) * 2004-10-12 2008-08-13 Merck Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
US7680778B2 (en) * 2007-01-19 2010-03-16 Microsoft Corporation Support for reverse and stemmed hit-highlighting
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
EP2571486A4 (en) * 2010-05-20 2013-12-04 Sun Pharma Advanced Res Co Ltd DRY POWDER INHALATION COMPOSITION
TWI399202B (zh) * 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
PH12014500440A1 (en) 2011-08-19 2014-04-28 Intech Biopharm Ltd Method for preparing metered dose sprayed inhaler for treating respiratory disease
CN102379846B (zh) * 2011-10-21 2014-07-02 江苏长风药业有限公司 以氢氟烷烃和聚乙二醇为辅料氟替卡松丙酸酯气雾剂制剂
AU2013259872B2 (en) 2012-05-08 2018-06-28 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
MX390453B (es) * 2014-06-25 2025-03-19 Optinose Inc Administracion nasal.
US20170189329A1 (en) 2014-07-29 2017-07-06 3M Innovative Properties Company Method of preparing a pharmaceutical composition
US11260052B2 (en) 2016-09-19 2022-03-01 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
MX387723B (es) 2016-09-19 2025-03-18 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende bromuro de glicopirronio, propionato de fluticasona y 1,1-difluoroetano.
MX384545B (es) 2016-09-19 2025-03-14 Mexichem Fluor Sa De Cv Composicion farmaceutica
WO2021195328A1 (en) * 2020-03-25 2021-09-30 Insmed Incorporated Pharmaceutical formulations of treprostinil prodrugs and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE629985A (https=) * 1962-11-29
CH634480A5 (de) * 1977-11-25 1983-02-15 Schwarzkopf Gmbh Hans Unter druck stehendes aerosolpraeparat.
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
JP2769925B2 (ja) * 1990-10-18 1998-06-25 ミネソタ マイニング アンド マニュファクチャリング カンパニー ベクロメタゾン１７，２１ジプロピオネートを含んで成るエアロゾル製剤
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
SK280911B6 (sk) * 1992-12-09 2000-09-12 Boehringer Ingelheim Pharmaceuticals, Inc. Farmaceutický prostriedok
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
NZ336049A (en) * 1996-12-04 2000-09-29 Bioglan Ireland R & D Ltd Aersol device for administering pharmaceutical active agents in a solution of propellant, carrier and valve means for delivering this to the exterior of the container
AU718967B2 (en) * 1997-02-05 2000-05-04 Jagotec Ag Medical aerosol formulations
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
CN1161104C (zh) * 1998-06-18 2004-08-11 贝林格尔·英格海姆药物公司 有二种或多种活性物质的气溶胶药物制剂
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6231519B1 (en) * 1999-05-04 2001-05-15 Nokia Corporation Method and apparatus for providing air quality analysis based on human reactions and clustering methods
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
AU7026800A (en) * 1999-09-11 2001-04-17 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
EE200200426A (et) * 2000-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasulikud pürimidiinkarboksamiidid

Also Published As

Publication number Publication date
EP1248597A1 (en) 2002-10-16
ES2238334T3 (es) 2005-09-01
DE60019167T2 (de) 2006-05-11
US20030032632A1 (en) 2003-02-13
JP2003518484A (ja) 2003-06-10
AU2206801A (en) 2001-07-09
EP1248597B1 (en) 2005-03-30
DE60019167D1 (de) 2005-05-04
WO2001047493A1 (en) 2001-07-05

Similar Documents

Publication Publication Date Title
ATE291898T1 (de) Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
DE60031504D1 (de) Fluticasonpropionat arzneizubereitung
DE60308997D1 (de) Formulierungen zur inhalation
PT1037604E (pt) Composicoes farmaceuticas de aerossol
ID29181A (id) Kombinasi formoterol dan garam tiotropium
CY1112562T1 (el) Φαρμακευτικες συνθεσεις για τη στοματικη χορηγηση της καλσιτονινης
PT1123120E (pt) Formulacao medicinal em aerossol
NZ298169A (en) Aerosol drug formulation; comprises hydrofluoroalkane propellant, medicament for inhalation and a surfactant
ID30171A (id) Kombinasi formoterol dan mometason furoat untuk asma
EP1135173A4 (en) MEDICINAL AEROSOL FORMULATION
DK1257254T3 (da) Formuleringer indeholdende et anticholinergt lægemiddel til behandling af kronisk obstruktiv lungesygdom
MXPA03001752A (es) Uso de la combinacion de salmeterol y propionato de fluticasona.
WO2002000191A3 (de) Bdellosomen
ATE286716T1 (de) Pharmazeutische formulierungen enthaltend salmeterol
WO2002007672A3 (en) A medicinal aerosol formulation
CA2446562A1 (en) Pharmaceutical formulation of fluticasone propionate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties